Common Stock
- Symbol
- TWST
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 3.02, 8.01, 9.01 · 8-K
Twist Bioscience Corporation
TWSTNASDAQEQUITYCurrent
Unregistered Sales of Equity Securities · Other Events
Item 3.02 Unregistered Sales of Equity Securities. The information set forth under Item 8.01 is incorporated into this Item 3.02 by reference. The shares to be issued as described below in Item 8.01 will be issued in transactions not involving any public offering in reliance upon an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended.
Company context
At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets. We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal - more experiments, more iterations, more chances for remarkable discoveries.
Current securities
Recent company filings
- Results of Operations and Financial ConditionNov 12, 2026
- SCHEDULE 13G/A - filed by Artisan Partners Limited Partnership regarding Twist Bioscience CorpNov 12, 2026
- SCHEDULE 13G - filed by STATE STREET CORP regarding Twist Bioscience CorpNov 10, 2026
- SCHEDULE 13G/A - filed by FMR LLC regarding Twist Bioscience CorpNov 5, 2026
- 144 filingSep 21, 2026
Registered securities in this filing
Twist Bioscience Corporation · 8-K · Filed 2026-02-17
Disclosure sections
Item 3.02Item 3.02 - Unregistered Sales of Equity
Item 3.02 Unregistered Sales of Equity Securities.
The information set forth under Item 8.01 is incorporated into this
Item 3.02 by reference.
The shares to be issued as described below in Item 8.01 will be issued
in transactions not involving any public offering in reliance upon an exemption from registration provided by Section 4(a)(2) of the
Securities Act of 1933, as amended.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
Pursuant to Stock Purchase Agreements entered into with certain investors
on February 11, 2026 (the “Stock Purchase Agreements”), Twist Bioscience Corporation (the “Company” or “Twist”)
will issue up to an aggregate of 632,328 shares (the “Shares”) of its common stock, par value $0.00001 per share (the “Common
Stock”). Of the Shares, the Company will issue up to 324,558 shares of Common Stock to Invenra Inc. (“Invenra”) and
pay $5 million in cash in consideration for a license agreement with Invenra and the transfer of certain technology from Invenra. In
addition, the Company will issue up to an aggregate of 307,770 shares of Common Stock to two investors of Invenra in consideration for
Invenra preferred stock for an approximately 6% ownership position in Invenra. The Company will also have the right to designate one
director to the Invenra board of directors (the “Invenra Board”), and the members of the Invenra Board (including the Twist
designee) also have the right, pursuant to a voting agreement, to approve two additional directors.
Concurrently with the entry into the Stock Purchase Agreements, the
Company entered into Registration Rights Agreements (the “Registration Rights Agreements”) with the investors. A form of
the Registration Rights Agreement is filed as Exhibit 4.1 to this Current Report on Form 8-K (this “Current Report”).
Pursuant to the Registration Rights Agreements, the Company is filing
a prospectus supplement to register the resale of the Shares. An opinion of Orrick, Herrington & Sutcliffe LLP is filed as Exhibit
5.1 to this Current Report in connection with the registration of the resale of the Shares.
Filed exhibits (1)
Exhibit 4.1 FORM OF REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated [●], 2026 (the “Agreement Effective Date”), is entered into by and among (i) Twist Bioscience Corporation, a Delaware corporation (the “Company”), and (ii) [●] (“Stockholder”). The Company and Stockholder may sometimes be referred herein individually as a “Party,” and collectively, as the “Parties.” Capitalized terms used but not defined in the Purchase Agreement (as defined below) shall have the respective meanings ascribed to such terms in the Agreement. BACKGROUND WHEREAS, concurrently with the execution of this Agreement, the Company and the Stockholder are parties to that Stock Purchase Agreement, of even date herewith (the “Purchase Agreement”), providing for the sale and issuance of a certain number of shares of the Company’s Common Stock, par value $0.00001 per share (the “Common Stock”), as more fully set forth in the Purchase Agreement (the “Twist Shares”). Capitalized terms used but not defined herein shall have the meaning assigned to them in the Purchase Agreement. AGREEMENT NOW, THEREFORE, the Parties, intending to be legally bound, hereby agree as foll…
Open exhibit ↗